Published in J Clin Oncol on September 08, 2015
Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med (2016) 1.03
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer (2016) 1.01
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol (2016) 0.95
The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget (2016) 0.94
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? Int J Mol Sci (2016) 0.90
Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res (2016) 0.89
Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother (2016) 0.89
Targeting Programmed Cell Death 1 in Ovarian Cancer. J Clin Oncol (2015) 0.84
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. J Gynecol Oncol (2016) 0.82
Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci (2017) 0.82
Ovarian cancer in 2015: Insights into strategies for optimizing ovarian cancer care. Nat Rev Clin Oncol (2015) 0.81
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Front Oncol (2017) 0.81
The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract (2016) 0.81
Major clinical research advances in gynecologic cancer in 2015. J Gynecol Oncol (2016) 0.81
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci U S A (2016) 0.80
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat Rev Drug Discov (2017) 0.80
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol (2016) 0.79
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. J Transl Med (2016) 0.79
Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. Int J Clin Oncol (2016) 0.79
Adoptive immunotherapy against ovarian cancer. J Ovarian Res (2016) 0.79
T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun Signal (2017) 0.78
PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.78
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Invest New Drugs (2016) 0.78
SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. Immunity (2017) 0.78
Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. Gynecol Oncol (2016) 0.77
Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. Hum Vaccin Immunother (2015) 0.77
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. Cancer Med (2016) 0.76
Features of Memory-Like and PD-1(+) Human NK Cell Subsets. Front Immunol (2016) 0.76
Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies. Int J Cancer (2016) 0.75
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. Front Immunol (2017) 0.75
Ovarian cancer patients' and their family members' perspectives on novel vaccine and virotherapy trials. Clin Trials (2016) 0.75
Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. Int J Mol Sci (2016) 0.75
Opportunities in immunotherapy of ovarian cancer. Ann Oncol (2016) 0.75
Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology (2016) 0.75
Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies. Oncology (Williston Park) (2016) 0.75
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J Cancer (2017) 0.75
Monocyte and interferon based therapy for the treatment of ovarian cancer. Cytokine Growth Factor Rev (2016) 0.75
Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. PLoS One (2017) 0.75
Therapeutic targets and new directions for antibodies developed for ovarian cancer. MAbs (2016) 0.75
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology (2016) 0.75
Update on immune checkpoint inhibitors in gynecological cancers. J Gynecol Oncol (2016) 0.75
Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: a phase II study. Cancer Sci (2017) 0.75
Targeted therapy in ovarian cancer. Womens Health (Lond Engl) (2016) 0.75
Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors? Hum Vaccin Immunother (2016) 0.75
IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecol Oncol (2017) 0.75
Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology (2017) 0.75
PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. Sci Rep (2017) 0.75
Immune checkpoint blockade in ovarian cancer. Memo (2016) 0.75
Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer. Sci Rep (2017) 0.75
PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol (2017) 0.75
Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer. J Gynecol Oncol (2017) 0.75
Harnessing the immune response to target tumors. F1000Res (2017) 0.75
Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer. Gynecol Oncol Rep (2017) 0.75
Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. Drug Des Devel Ther (2017) 0.75
New use of microsatellite instability analysis in endometrial cancer. Oncol Lett (2017) 0.75
NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol (2017) 0.75
Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies. Gynecol Oncol Res Pract (2016) 0.75
A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). Cancer Chemother Pharmacol (2017) 0.75
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. J Transl Med (2017) 0.75
Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J Gynecol Oncol (2017) 0.75
Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. J Neurooncol (2017) 0.75
The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma. Oncoimmunology (2017) 0.75